Acquisition of patent grant in Europe for “Conversational Dementia Diagnosis Support AI Program”

Home » corporate » News » 2023 » Acquisition of patent grant in Europe for “Conversational Dementia Diagnosis Support AI Program”
2023.08.21 Press release

--To the press -

Acquisition of patent grant in Europe for “Conversational Dementia Diagnosis Support AI Program”

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) is pleased to announce that it has received a patent allowance notification from the European Patent Office for the "Conversational Dementia Diagnosis Support AI Program". .

 The "Conversational Dementia Diagnosis Support AI Program" uses FRONTEO's natural language analysis AI engine "KIBIT" to detect the presence or absence of cognitive decline from a natural conversation between a medical practitioner and a patient for about 5 to 10 minutes. It's a screening program.As the global population ages and medical costs related to dementia increase year by year, we are promoting research and development with the aim of improving prognosis through early detection of dementia, reducing the burden of dementia diagnosis, and using it as a new digital biomarker. I'm here.

 FRONTEO has registered patent rights for this program in Japan in July 2020 and in South Korea in August 7, and has exclusive development and sales in the United States, Europe, China, and South Korea with Keio University. has a contract1).We believe that the acquisition of a patent grant in Europe is an important step in expanding this program to overseas markets.This patent is scheduled to be registered in Germany, France, Italy, the United Kingdom, and Spain.

 国際アルツハイマー病協会の報告によると、世界のアルツハイマー型認知症患者数は20年ごとにほぼ2倍に増加し、2020年の5866万人から2030年に8205万人、2040年に1億1483万人、2050年には約1億5224万人に達すると推計されており2), Dementia measures are an important issue not only in Japan but also worldwide. FRONTEO will continue to contribute to solving medical and social issues associated with aging and improving the QOL of the elderly through research and development and commercialization of AI technology.

 The impact of this matter alone on the Company's business performance will be minor.

1) FRONTEO: Concluded a global license agreement with Keio University for the “Conversational Dementia Diagnosis Support AI Program”. https://www.fronteo.com/20210629
2) Alzheimer's Disease International: Numbers of people with dementia worldwide, https://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/[Confirmed on August 2023.8.8, XNUMX]


■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 thousand yen (as of March 26, 3,042,317).

* FRONTEO and KIBIT are registered trademarks of FRONTEO in Japan.

 

<Contact for inquiries from the press>
PR Department, FRONTEO, Inc.
Email: pr_contact@fronteo.com

<Contact for inquiries regarding the life science AI business>
Life Science AI Business Department, FRONTEO, Inc.
https://lifescience.fronteo.com/contact